Inactive Instrument

Analyst Reco. XOMA Corp Nasdaq

Equities

HC Wainwright Adjusts Price Target on XOMA to $74 From $69, Maintains Buy Rating	23-08-09	MT
XOMA : Wedbush Suspended Coverage on XOMA	21-10-11	MT
XOMA : HC Wainwright Adjusts XOMA's Price Target to $69 from $56, Keeps Buy Rating	21-10-08	MT
XOMA : Aegis Capital Adjusts XOMA Price Target to $56 From $60, Maintains Buy Rating	21-09-09	MT
Wedbush Downgrades XOMA to Neutral From Outperform, Adjusts PT to $22 From $41	21-09-07	MT
XOMA : Wedbush Downgrades XOMA to Neutral From Outperform, Adjusts PT to $22 From $41	21-09-07	MT
XOMA : Aegis Capital Starts XOMA at Buy with $20.68 Price Target	21-06-29	MT
XOMA : Wedbush Adjusts XOMA's Price Target to $41 From $36, Citing Iscalimab, Cetrelimab Projections; Outperform Rating Kept	21-03-19	MT
XOMA : Wedbush Adjusts XOMA's Price Target to $36 From $29 on Vicineum Sales Forecast, Keeps Outperform Rating	20-11-27	MT

No results for this search